MX2021012033A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2021012033A
MX2021012033A MX2021012033A MX2021012033A MX2021012033A MX 2021012033 A MX2021012033 A MX 2021012033A MX 2021012033 A MX2021012033 A MX 2021012033A MX 2021012033 A MX2021012033 A MX 2021012033A MX 2021012033 A MX2021012033 A MX 2021012033A
Authority
MX
Mexico
Prior art keywords
gilteritinib
medicinal composition
sweetener
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2021012033A
Other languages
English (en)
Inventor
Akihiko Sasaki
Ko Tanaka
Masakazu Miyazaki
Seiji Takae
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2021012033A publication Critical patent/MX2021012033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica que contiene 6-etil-3-{3-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]-an ilino}-5-[(oxan-4-il)amino]pirazina-2-carboxamida o una sal aceptable farmacéuticamente de la misma y un edulcorante para reducir el amargor o una sal aceptable farmacéuticamente de la misma y un edulcorante para reducir el amargor de gilteritinib, suprimir la disminución en estabilidad de disolución de gilteritinib debido a, por ejemplo, estrés como calor y/o humedad al paso del tiempo, y que tiene excelente estabilidad de disolución. La composición farmacéutica contiene gilteritinib o una sal aceptable farmacéuticamente de la misma, un edulcorante, y azúcares y/o alcoholes de azúcar.
MX2021012033A 2019-04-03 2020-04-02 Composicion farmaceutica. MX2021012033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019070997 2019-04-03
PCT/JP2020/015225 WO2020204142A1 (ja) 2019-04-03 2020-04-02 医薬組成物

Publications (1)

Publication Number Publication Date
MX2021012033A true MX2021012033A (es) 2021-11-03

Family

ID=72668177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012033A MX2021012033A (es) 2019-04-03 2020-04-02 Composicion farmaceutica.

Country Status (11)

Country Link
US (1) US20220152020A1 (es)
EP (1) EP3949952B1 (es)
JP (1) JP6822619B1 (es)
KR (1) KR20210148252A (es)
CN (1) CN113677330B (es)
CA (1) CA3131461C (es)
MX (1) MX2021012033A (es)
PT (1) PT3949952T (es)
SG (1) SG11202110315SA (es)
TW (1) TWI836051B (es)
WO (1) WO2020204142A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018192A1 (ja) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 口腔内崩壊錠剤
WO2008119033A1 (en) * 2007-03-27 2008-10-02 Eurand, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
RS54552B1 (en) 2009-05-08 2016-06-30 Astellas Pharma Inc. UNIT OF DIAMINO HETEROCYCLIC CARBOXAMIDE
IT1406107B1 (it) * 2010-12-13 2014-02-14 Alfa Wassermann Spa Composizioni solide comprendenti antiinfiammatori non steroidei, processi per la loro preparazione e loro uso.
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
JP6549428B2 (ja) * 2014-07-23 2019-07-24 エスエス製薬株式会社 経口組成物
FI3318259T3 (fi) * 2015-07-03 2023-03-20 Astellas Pharma Inc Stabiili farmaseuttinen koostumus annettavaksi suun kautta
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
KR20180124055A (ko) * 2016-03-29 2018-11-20 아스테라스 세이야쿠 가부시키가이샤 급성 골수성 백혈병의 치료를 위한 병용 요법
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物

Also Published As

Publication number Publication date
CA3131461C (en) 2024-06-25
EP3949952B1 (en) 2024-07-17
WO2020204142A1 (ja) 2020-10-08
JPWO2020204142A1 (ja) 2021-04-30
TW202103702A (zh) 2021-02-01
CA3131461A1 (en) 2020-10-08
EP3949952A4 (en) 2022-12-21
CN113677330A (zh) 2021-11-19
US20220152020A1 (en) 2022-05-19
JP6822619B1 (ja) 2021-01-27
CN113677330B (zh) 2023-10-31
EP3949952A1 (en) 2022-02-09
SG11202110315SA (en) 2021-10-28
PT3949952T (pt) 2024-09-13
KR20210148252A (ko) 2021-12-07
TWI836051B (zh) 2024-03-21

Similar Documents

Publication Publication Date Title
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
NO20083104L (no) Fast preparat
MXPA04001114A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
KR20080014002A (ko) 분산가능 정제
NO20052041L (no) Administrasjonsform for farmasoytisk aktive peptider med vedvarende frigivelse og fremgangsmate for fremstilling av denne
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
EP2377557A3 (en) Compositions comprising azelastine and methods of use thereof
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
UA94916C2 (ru) Композиция тразодона для введения один раз в день
HUP0102676A2 (hu) Szilárd, gyorsan széteső cetirizint tartalmazó gyógyszerkészítmények
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
NO20084276L (no) Orodispergerbare domperidontabletter
WO2005018605A3 (en) Novel formulation of ropinirole
MX2021012033A (es) Composicion farmaceutica.
TW200740424A (en) Taste masking dosage form
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
HUP0401484A2 (hu) BIBN4096 alkalmazása kombinációban más migrénellenes szerekkel migrén kezelésére és a kombinációt tartalmazó gyógyszerkészítmények
Ruggenenti The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs
NO20081035L (no) Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet
EP2662077B1 (en) Effervescent compositions containing n-acetylcysteine